Daraxonrasib, sold as Rasonque, has produced encouraging results in pancreatic cancer studies, but its benefits come with documented risks. Skin reactions, diarrhea and mouth inflammation are common. US prescribing information also warns about less frequent complications involving the bowel and lungs.

How often do side effects occur, which symptoms need prompt medical attention, and what can the latest trial of daraxonrasib plus chemotherapy tell us about safety? The distinction between the FDA-approved treatment and the investigational combination is essential.

What are the most common daraxonrasib side effects?

The US Food and Drug Administration’s prescribing information describes the phase 3 RASolute 302 trial, in which 241 patients with metastatic pancreatic adenocarcinoma received daraxonrasib and 214 received a physician’s choice of chemotherapy.

Among people receiving daraxonrasib, the reported frequencies of selected adverse reactions were:

Adverse reactionDaraxonrasib patients
Rash87%
Diarrhea67%
Mouth inflammation or sores (stomatitis)56%
Nausea52%
Fatigue47%
Vomiting42%
Abdominal pain27%
Swelling (edema)25%

These percentages come from the RASolute 302 monotherapy trial, not the recent first-line combination trial. They represent adverse events recorded in that study population; the percentage for an individual patient can differ. The study also reported changes in blood counts and other laboratory values.

In the FDA label, 30% of patients receiving daraxonrasib had a serious adverse reaction, while 2.9% discontinued the drug permanently because of an adverse reaction. Dose interruptions and reductions were more frequent, at 69% and 37%, respectively. These figures measure different outcomes and should not be combined.

What does the FDA warn about beyond common symptoms?

The label’s warnings and precautions cover several clinically important risks.

Skin and soft tissue reactions. These can include rash, itching, dry skin, fissures and inflammation around the nails. In a pooled safety population, dermatologic reactions were reported in 86% of patients, including grade 3 reactions in 10%. The label recommends preventive skin care and clinical monitoring.

Stomatitis and oral disorders. Mouth sores and inflammation occurred in 57% of the pooled population, with grade 3 effects in 9%. Painful mouth symptoms can interfere with eating and drinking and warrant discussion with the treatment team.

Diarrhea. This occurred in 63% of the pooled population, including grade 3 diarrhea in 6%. Persistent diarrhea raises concerns about dehydration and requires clinical assessment.

Gastrointestinal perforation. A hole in the wall of the gastrointestinal tract was reported in 0.9% of the pooled safety population, including severe and fatal events.

Interstitial lung disease or pneumonitis. Lung inflammation occurred in 2.4% of the pooled population; some events were severe and a fatal case was reported.

Pregnancy risk. The label warns of potential harm to an embryo or fetus, based on animal studies.

The pooled warning figures reflect 425 patients across RASolute 302 and the earlier RMC-6236-001 study. That is why some percentages differ from the 241-patient comparison-trial table. They describe different groups and sometimes different definitions of events.

Which symptoms require urgent medical assessment?

The prescribing information calls for monitoring signs of potential gastrointestinal perforation and new or worsening lung problems. Sudden severe abdominal pain, particularly with a rigid abdomen, fever, faintness or rapid deterioration, calls for emergency medical assessment. New or worsening breathlessness, chest discomfort or persistent cough also requires prompt medical contact.

Severe or persistent diarrhea, inability to keep fluids down, extensive painful rash, or mouth sores preventing eating or drinking should be reported promptly to the treating oncology team. Fever during chemotherapy may be an emergency, particularly when blood counts are low.

The FDA label provides clinician-directed instructions for withholding treatment, adjusting doses and supportive medicines according to severity. Those decisions belong to the treating medical team. A patient should use the oncology service’s emergency contact arrangements for individual instructions.

What do the new daraxonrasib-plus-chemotherapy results show?

On November 19–20, 2026, Revolution Medicines presented updated phase 1/2 results from the open-label RMC-GI-102 study. The first-line metastatic pancreatic cancer cohort included 61 patients given daraxonrasib with gemcitabine and nab-paclitaxel.

The company reported a 60.7% confirmed tumor response rate and described the combination’s overall safety profile as consistent with previously observed effects of the component treatments.

That description matters, but the combination analysis was small and non-randomized. It cannot establish that the regimen is safer than standard chemotherapy, nor can side-effect percentages from the FDA-approved monotherapy trial be applied directly to a different drug combination. The added chemotherapy can contribute its own adverse events, including changes to blood counts and infection risk.

The ongoing randomized RASolute 303 trial is evaluating daraxonrasib alone, daraxonrasib plus chemotherapy and chemotherapy alone as first-line approaches. It is designed to provide stronger comparisons of efficacy and safety.

The full November results, their limitations and the phase 3 study are explained in our report on daraxonrasib’s 60.7% tumor response result.

Is the combination approved for pancreatic cancer?

Daraxonrasib itself received US FDA approval on August 26, 2026 for adults with metastatic pancreatic adenocarcinoma who have already received at least one systemic therapy or are unsuitable for multiagent systemic therapy. The European Commission has also approved the drug for adults with metastatic pancreatic adenocarcinoma following at least one prior systemic therapy.

Those authorizations are different from approval of the first-line daraxonrasib-plus-chemotherapy regimen discussed in November. The first-line combination remains under clinical investigation. Breakthrough therapy designation is intended to accelerate development and review; it does not, by itself, authorize a new use.

For regulatory status by region, see our guide to daraxonrasib access in the US, EU and UK.

What should patients take away from the safety data?

Rash, diarrhea, mouth inflammation, nausea and fatigue are well-documented potential side effects of daraxonrasib. Uncommon but serious gastrointestinal and lung complications are specifically identified in US prescribing information. Clinical monitoring and rapid reporting of significant symptoms are part of safe treatment.

The promising November 2026 results for combining the drug with chemotherapy are an early signal, while the detailed comparative benefit-risk assessment still depends on randomized evidence. Treatment and toxicity management should be individualized by an oncology team using the current prescribing information.